TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

Gastroesophageal Reflux Disease (GERD) Clinical Trial

— TAK-438_107  

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Multiple Repeat Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Non-Japanese Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02141711
• Other study ID #: TAK-438_107
• Secondary ID: U1111-1153-84432
• Status: Completed
• Phase: Phase 1
• First received: May 15, 2014
• Last updated: May 15, 2014
• Start date: October 2008
• Est. completion date: February 2009

Study information

• Verified date: May 2014
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.

Description:

The drug being tested in this study is called TAK-438. TAK-438 is being tested to find a safe and well-tolerated dose. This study looked at pharmacokinetic (effect of the body on the drug) and pharmacodynamic properties (effect of the drug on the body) as well as look at lab results and side effects in people who took TAK-438. This study was designed as a randomized, sequential-panel, multiple repeat dose study.

The study population consisted of 4 Cohorts with 12 participants in each Cohort; with 9 participants randomized to receive a single dose of TAK-438, and 3 participants to receive placebo. Participants in each Cohort received a single dose of study drug once daily after a 10-hour fast. The starting dose was 10 mg followed by administrations of 20, 40, and 30 mg.

This single-centre trial was conducted in the United Kingdom. The overall time to participate in this study was up to 37 days. Participants made 2 visits to the clinic for screening, one 11-day period of confinement to the clinic, and 2 further visits after the confinement period. All participants were contacted by telephone 7 days after last dose of study drug for a follow-up assessment.

Other known NCT identifiers

• NCT01873209

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male subjects aged 18 to 45, inclusive, who are in good health, as determined by medical history, physical examination, clinical laboratory evaluations and urine drug screen.

• The subject has the ability to tolerate the pH probe for 24 hours prior to Randomization (Day 1).

Exclusion Criteria:

• Clinically significant history of hypersensitivity to any drug or food or any excipients of TAK-438

• History of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer,gastric ulcer, dyspepsia, Barrett's esophagus, or Zollinger-Ellison syndrome

• The subject has a positive test result for Helicobacter pylori at the Initial Screening Visit

• Any clinically significant results from physical examinations or clinical laboratory results as deemed by the investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Erosive Esophagitis(EE)
• Esophagitis
• Gastroesophageal Reflux
• Gastroesophageal Reflux Disease (GERD)

Intervention

Drug:
• TAK-438
TAK-438 tablets
• TAK-438 Placebo
TAK-438 placebo-matching tablets

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC[0-tlqc]).	Days 1 and 7	No
Primary	AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.	Days 1 and 7	No
Primary	AUC(0-tau): Area Under the Plasma Concentration-time Curve from Time 0 to Time tau Over the Dosing Interval for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	AUC(0-tau) is a measure of the area under the plasma concentration-time curve from time 0 to time tau over a dosing interval, where tau is the length of the dosing interval.	Days 1 and 7	No
Primary	Cmax: Maximum Observed Plasma Concentration for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.	Days 1 and 7	No
Primary	Cmin,ss: Minimum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul		Day 7	No
Primary	Cmax,ss: Maximum Observed Plasma Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul		Day 7	No
Primary	(Cmax-Cmin)/Cavg: Fluctuation of Concentration at Steady State for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	(Cmax-Cmin)/Cavg, where Cmin is the minimum observed plasma concentration and Cavg is the average plasma concentration at steady state.	Day 7	No
Primary	Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.	Days 1 and 7	No
Primary	Terminal Elimination Rate Constant (?z) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Terminal elimination rate constant (?z) is the rate at which drugs are eliminated from the body.	Days 1 and 7	No
Primary	Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.	Days 1 and 7	No
Primary	Apparent Clearance (CL/F) Pharmacokinetic Parameter for TAK-438	CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr.	Days 1 and 7	No
Primary	Apparent Volume of Distribution (Vz/F) for TAK-438	Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by ?z.	Days 1 and 7	No
Primary	Ae(0-t): Total Amount of Drug Excreted in Urine from Time 0 to Time T for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Ae(0-t) is the total amount of drug excreted in urine from time 0 to t, where t is 24 hours on Day 1 and 48 hours on Day 7.	Day 1 and Day 7	No
Primary	Ae(0-tau): Total Amount of Drug Excreted in Urine from Time 0 to Time tau for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	Ae(0-tau) is the total amount of drug excreted in urine from time 0 to tau, where tau equals 24 hours.	Day 1 and Day 7	No
Primary	Renal Clearance (CLr) for TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul	CLr is a measure of apparent clearance of the drug from the urine calculated as total amount excreted in the urine from time 0 to 24 hours postdose / plasma area under the curve from time 0 to 24 hours post-dose.	Day 1 and Day 7	No
Primary	Fraction of TAK-438 and TAK-438 metabolites M-I, M-II, M-III and M-IV-Sul Excreted in Urine (Fe)	Fe is a measure of the fraction of drug excreted in urine and is calculated as Fe = (total amount excreted in the urine from time 0 to 24 hours post-dose / dose)×100.	Day 1 and Day 7	No
Primary	Physical Examination Findings	A baseline physical examination (defined as the pretreatment assessment immediately prior to the start of study drug) will consist of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; (11) genitourinary system; and (12) other. All subsequent physical examinations should assess clinically significant changes from the baseline examination.	Baseline up to Day 9	Yes
Primary	Number of Participants With Potentially Clinically Significant Vital Sign Findings	Participants with at least one potentially clinically significant post-baseline vital sign finding. Vital signs will include body temperature (oral temperature), sitting blood pressure (after sitting for 5 minutes), and pulse (bpm).	Baseline up to Day 9	Yes
Primary	Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings	Full 12-lead ECGs will be recorded using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (using Bazett correction; QTcB) intervals. The investigator or other qualified physician will interpret each ECG using one of the following categories: within normal limits, abnormal but not clinically significant, or abnormal and clinically significant.	Baseline to Day 9	Yes
Primary	Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings	Laboratory tests for hematology, serum chemistries, coagulation tests, and urinalysis will be performed.	Baseline up to Day 9	Yes
Primary	Number of Participants With Treatment-Emergent Adverse Events (AEs)	Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 7 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug.	Baseline up to Day 9	Yes
Primary	Safety of TAK-438	Assessed by physical examination, ECG, and safety tests of blood/urine	3 months	Yes
Primary	Tolerability of TAK-438	Assessed by adverse events	3 months	Yes
Primary	Pharmacokinetic analysis of plasma TAK-438 concentrations	Primary pharmacokinetic parameters (AUC (0-tlqc), AUC (0-inf), Cmax) for TAK-438 and its metabolites M-I, M-II, M-III and M-IV-Sul will be subject to statistical analysis	3 months	Yes
Primary	Pharmacodynamic measurement for assay of gastric pH, measurement of gastrin, pepsinogen I, pepsinogen II and the pepsinogen I/II ratio in plasma samples		3 months	Yes
Secondary	Percentage of Time the pH is Greater than pH 4 and pH 5 over a 24 Hour Period	Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7.	Over a 24-hour period at Baseline and over a 24-hour period following the administration of study on Days 1, 4 and 7	No
Secondary	Percentage of Time the pH is Greater than pH 4 and pH 5 over a 48 Hour Period	Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 48-hour period following the administration of study drug on Day 7.	Over a 48-hour period following the administration of study on Day 7	No
Secondary	Percentage of Time the PH is Greater than pH 4 and pH 5 from 8 PM to 8 AM	Using a calibrated gastric pH monitor, the measurement of stomach pH will be made continuously over a 12-hour period from 8 PM to 8 AM to assess nocturnal pH.	Over a 12-hour period from 8 PM to 8 AM on Days 1, 4 and 7	No
Secondary	Total Amount of Gastrin in Plasma		Predose Days 1 through 7 and Days 8 and 9	No
Secondary	Total Amount of Pepsinogen I in Plasma		Predose Days 1 through 7 and Days 8 and 9	No
Secondary	Total Amount of Pepsinogen II in Plasma		Predose Days 1 through 7 and Days 8 and 9	No
Secondary	Pepsinogen I/II Ratio in Plasma		Predose Days 1 through 7 and Days 8 and 9	No